Phase II study of linifanib in KRAS mutated metastatic refractory colorectal cancer

被引：0
|
作者：
Chan, E. [1 ]
Ayers, G. D. [2 ]
Goff, L. [1 ]
McClanahan, P. [3 ]
Holloway, M. [3 ]
Ciombor, K. [1 ]
Smith, S. J. [1 ]
Ancell, K. [1 ]
Cardin, D. B. [1 ]
Berlin, J. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Div Med Oncol, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Ctr Quantitat Sci, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2369
引用
收藏
页码：S549 / S549
页数：1
相关论文
共 50 条
  • [31] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [32] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [33] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
  • [34] QUANTITATIVE MEASUREMENT OF KRAS MUTATED ALLELES IN PLASMA AS PROGNOSTIC MARKER IN METASTATIC KRAS MUTANT COLORECTAL CANCER
    Spindler, K.
    Pallisgaard, N.
    Andersen, R.
    Jakobsen, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 530 - 531
  • [35] Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC)
    Becerra, C.
    Salazar, R.
    Garcia-Carbonero, R.
    Thomas, A. L.
    Vazquez-Mazon, F.
    Cassidy, J.
    Maughan, T.
    Gallen, M.
    Iveson, T.
    Hixon, M.
    Gualberto, A.
    Yin, D.
    Bergsland, E. K.
    Li, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Kras in metastatic colorectal cancer
    Wicki, Andreas
    Herrmann, Richard
    Christofori, Gerhard
    SWISS MEDICAL WEEKLY, 2010, 140 : 14 - 19
  • [37] Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
    Monge, Cecilia
    Xie, Changqing
    Myojin, Yuta
    Coffman, Kelley
    Hrones, Donna Mabry
    Wang, Sophie
    Hernandez, Jonathan M.
    Wood, Bradford J.
    Levy, Elliot B.
    Juburi, Israa
    Hewitt, Stephen M.
    Kleiner, David E.
    Steinberg, Seth M.
    Figg, William D.
    Redd, Bernadette
    Homan, Philip
    Cam, Maggie
    Ruf, Benjamin
    Duffy, Austin G.
    Greten, Tim F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [38] Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).
    Fogelman, David R.
    Kochenderfer, Mark D.
    Saylors, Gene Brian
    Braiteh, Fadi S.
    Nemunaitis, John J.
    Cohn, Allen Lee
    O'Neill, Peter
    Zhou, Li
    Switzky, Julie C.
    Assad, Albert
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] A phase II study of pembrolizumab, binimetinib, and bevacizumab in patients with microsatellitestable, refractory, metastatic colorectal cancer (mCRC)
    Friedrich, Tyler
    Blatchford, Patrick Jud
    Lentz, Robert William
    Davis, S. Lindsey
    Kim, Sunnie S.
    Leal, Alexis Diane
    Van De Voorde, Zoe
    Lee, Matthew R.
    Waring, Meredith
    Cull, Tiffany
    Martin, Anne
    Eckhardt, S. Gail
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [40] A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.
    Overman, Michael J.
    Eng, Cathy
    Kee, Bryan K.
    Fogelman, David R.
    Fark, Christine
    Hippert, Rick
    Holter, Scott
    Issa, Jean-Pierre
    Hamilton, Stanley R.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345